Compounded Tirzepatide: What It Is, Dosage and How It Works

Key Takeaways

• Tirzepatide acts on two appetite signals, GIP and GLP-1, and may help reduce hunger and cravings.
• It may help you lose weight as part of a provider-guided plan.
• A compounded prescription is prepared by a licensed pharmacy for you, to the prescription your provider writes.
• Your provider reviews your health history and required labs before deciding what to prescribe.
• Before each refill, your provider reviews how you're doing and adjusts your plan as needed.

When hunger keeps getting in the way, willpower isn't the whole story. In a national survey of US adults with obesity, 49% said controlling hunger was a barrier to starting a weight-loss effort. Appetite is driven by signals your body sends, and tirzepatide works on those signals.

How Can Tirzepatide Help With Hunger?

Tirzepatide activates two hormone receptors involved in appetite, GIP and GLP-1. The Zepbound prescribing information describes GLP-1 as a natural regulator of appetite and calorie intake, with receptors in the areas of the brain that manage it.

Approved tirzepatide injections reduce calorie intake, likely through their effects on appetite. In a six-week study of adults who were overweight or living with obesity, tirzepatide reduced hunger before meals and food cravings. That can mean fewer moments where hunger is in charge.

Tell your provider what hits hardest, whether that's hunger between meals, cravings for sweets or rich foods, or something else. Your plan can be built around it.

What Results Can Look Like

In a large study of adults taking approved tirzepatide injections, people still on treatment lost an average of 5.9% of their starting weight at 3 months, 10.1% at 6 months and 15.3% at 12 months. Results differ from person to person, so you and your provider review your progress as you go.

What Does a Compounded Prescription Mean?

It means your medicine is made for you. A licensed compounding pharmacy prepares it to the prescription your provider writes, rather than a manufacturer making it for everyone. Our guide to compounded medicines explains more.

Compounded tirzepatide: Medicine containing tirzepatide, prepared by a licensed compounding pharmacy for one patient's prescription.

Zepbound: An FDA-approved tirzepatide product with its own prescribing information.

LIV offers both. Your provider reviews which option fits your health history and goals, and your prescription tells you exactly which medicine you're using and how to use it.

How Your Provider Builds Your Plan

Your plan starts with an evaluation. A licensed provider reviews your health history, the medicines you take and your required labs, then decides whether tirzepatide is right for you.

If it is, your provider chooses your dose and schedule. Follow the instructions supplied with your medicine, and ask your provider or pharmacist about anything that's unclear. For a compounded vial, the amount you draw into a syringe depends on that vial's concentration, so always go by your own prescription.

Our tirzepatide dosing guide explains how to read those measurements, and the injection-site guide covers where to inject.

Start with an evaluation

Side Effects and Safety Notes

The most common side effects listed on the Zepbound label are stomach-related: nausea, diarrhea, vomiting, constipation, abdominal pain and indigestion.

Tirzepatide isn't right for everyone. Your provider will ask about:

• Thyroid history: a personal or family history of medullary thyroid cancer or MEN 2.
• Past conditions: pancreatitis, gallbladder disease or kidney problems.
• Other medicines: especially diabetes medicines that can lower blood sugar.
• Allergies: any serious allergic reaction to a medicine.

Contact your provider promptly about severe or lasting stomach pain, ongoing vomiting or signs of dehydration.

What Happens as Your Plan Continues?

Before each refill, you tell LIV how you're doing, and your provider reviews that update along with your plan. Bring up changes in appetite, any side effects and anything that's hard about the routine. Ask before changing your dose or schedule, so every adjustment fits your progress.

Start with an evaluation

Bring Your Weight Goals Into Focus

Start with what you want help with, and bring your questions about hunger, the medicine and the routine. Your provider will walk you through the options and how your progress will be reviewed.

An evaluation is the next step in discussing whether compounded tirzepatide, Zepbound or another option is right for you.

Frequently Asked Questions

What did studies of tirzepatide find?

In a six-week study, adults who were overweight or living with obesity and took tirzepatide reported less hunger before meals and fewer food cravings than those taking a placebo. The study didn't test a compounded preparation, and results vary from person to person, so your provider will check in on how you're doing.

Where do the weight-loss figures come from?

From a real-world observational study of 18,386 matched adults receiving an approved tirzepatide or semaglutide injection (Rodriguez et al., JAMA Internal Medicine, 2024); 52% had type 2 diabetes. The figures describe people still on treatment, and each timepoint is a separate estimate, so they shouldn't be added together. The tirzepatide injection studied is approved for type 2 diabetes, so its use for weight management was off-label, and the results concern approved injections, not a compounded preparation. Individual results vary. Doses weren't verified, more than half of people stopped treatment during follow-up (52.5% of those on semaglutide and 55.9% on tirzepatide), and missing weights were estimated statistically.

Is compounded tirzepatide the same as Zepbound?

They contain the same active ingredient, but they're different products. Zepbound is FDA-approved. A compounded preparation is made by a licensed pharmacy for one patient's prescription, and it isn't a generic version of Zepbound. Compounded medicines aren't FDA-approved, and the FDA doesn't review their safety, effectiveness or quality before they're marketed.

What does the boxed warning on Zepbound say?

The Zepbound label carries a boxed warning about thyroid C-cell tumors. Tirzepatide caused these tumors in rats; it isn't known whether it does in people. Zepbound isn't for anyone with a personal or family history of medullary thyroid cancer or MEN 2, or a serious allergy to tirzepatide. In the label's weight-management trials, 25% to 29% of adults taking it reported nausea, compared with 8% on placebo. The label also says it isn't recommended for severe gastroparesis, and to tell your care team before any procedure with anesthesia or deep sedation. The label notes that routine blood tests (calcitonin) or thyroid ultrasound are of uncertain value for catching these tumors early, so tell your provider about a lump in your neck, trouble swallowing, shortness of breath or hoarseness that doesn't go away.

Will my prescription tell me how much to take?

Yes. Follow the dose and instructions supplied for your medicine. If you're unsure about the vial concentration, syringe markings or schedule, ask your provider or pharmacist before using it.

Why is tirzepatide compared with semaglutide?

Both act on the GLP-1 receptor, which is involved in appetite. Tirzepatide also acts on the GIP receptor. Your history and goals guide the choice with your provider.

References

Kaplan, L. M., Golden, A., Jinnett, K., Kolotkin, R. L., Kyle, T. K., Look, M., et al. (2018). Perceptions of barriers to effective obesity care: Results from the National ACTION Study. Obesity, 26(1), 61-69. https://pubmed.ncbi.nlm.nih.gov/29086529/

Rodriguez, P. J., Goodwin Cartwright, B. M., Gratzl, S., et al. (2024). Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Internal Medicine, 184(9), 1056-1064. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080

Eli Lilly and Company. (2026). Zepbound prescribing information. DailyMed. Clinical Pharmacology, Boxed Warning, Contraindications, Warnings and Precautions, and Adverse Reactions. Read September 11, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b

Tirzepatide on ingestive behavior in adults with overweight or obesity: A randomized 6-week phase 1 trial. (2025). Nature Medicine. doi:10.1038/s41591-025-03774-9. Read September 11, 2026. https://www.nature.com/articles/s41591-025-03774-9

U.S. Food and Drug Administration. (n.d.). Compounding and the FDA: Questions and answers. Read September 11, 2026. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers